gatifloxacin has been researched along with Complication, Postoperative in 18 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our goal was to report a new case of gatifloxacin-related hyperglycemia in a nondiabetic patient with acute renal dysfunction." | 7.73 | Hyperglycemia and gatifloxacin: a case report and summary of current literature. ( Beste, LA; Mersfelder, TL, 2005) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 7.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| "Our goal was to report a new case of gatifloxacin-related hyperglycemia in a nondiabetic patient with acute renal dysfunction." | 3.73 | Hyperglycemia and gatifloxacin: a case report and summary of current literature. ( Beste, LA; Mersfelder, TL, 2005) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 3.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| "The intraocular pressure was slightly higher in Group II (p<0." | 2.78 | Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components. ( Avakian, A; Brasil, A; Cunha, PA; Shinzato, FA; Tecchio, GT; Weber, SL, 2013) |
| "Bacterial endophthalmitis is a potential complication of ICL implantation." | 1.35 | Culture-positive endophthalmitis after implantation of intraocular Collamer lens. ( Cohen, JA; Davis, MJ; Dennis, RF; Epstein, RJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (94.44) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunha, PA | 1 |
| Shinzato, FA | 1 |
| Tecchio, GT | 1 |
| Weber, SL | 1 |
| Brasil, A | 1 |
| Avakian, A | 1 |
| Jensen, MK | 2 |
| Fiscella, RG | 2 |
| Moshirfar, M | 4 |
| Mooney, B | 1 |
| Tsuchiya, Y | 1 |
| Kobayakawa, S | 1 |
| Tsuji, A | 1 |
| Tochikubo, T | 1 |
| Lindstrom, RL | 1 |
| Holland, EJ | 1 |
| Lane, SS | 1 |
| McCulley, JP | 1 |
| Callegan, MC | 1 |
| Novosad, BD | 1 |
| Ramadan, RT | 1 |
| Wiskur, B | 1 |
| Moyer, AL | 1 |
| Davis, MJ | 1 |
| Epstein, RJ | 1 |
| Dennis, RF | 1 |
| Cohen, JA | 1 |
| Brogan, SE | 1 |
| Cahalan, MK | 1 |
| Marx, DP | 1 |
| Kumar, R | 1 |
| Beste, LA | 1 |
| Mersfelder, TL | 1 |
| Mirzaian, G | 1 |
| Feiz, V | 2 |
| Kang, PC | 1 |
| Hamam, RN | 1 |
| Noureddin, B | 1 |
| Salti, HI | 1 |
| Haddad, R | 1 |
| Khoury, JM | 1 |
| Deramo, VA | 1 |
| Lai, JC | 1 |
| Fastenberg, DM | 1 |
| Udell, IJ | 1 |
| Sahu, SK | 1 |
| Murthy, SI | 1 |
| Sangwan, VS | 1 |
| Thomas, R | 1 |
| Vitale, AT | 1 |
| Wegelin, JA | 1 |
| Basavanthappa, S | 1 |
| Wolsey, DH | 1 |
| Balzli, CL | 1 |
| McCormick, CC | 1 |
| Caballero, AR | 1 |
| Huang, B | 1 |
| Wigington, L | 1 |
| Smith, E | 1 |
| Tang, A | 1 |
| O'Callaghan, RJ | 1 |
| Bohigian, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.[NCT00892918] | 40 participants (Anticipated) | Interventional | 2009-06-30 | Not yet recruiting | |||
| The Effects on Betadine 5% Penetration When Using Lidocaine 2% Jelly Versus Topical Tetracaine 0.5% for Topical Phacoemulsification Cataract Surgery.[NCT00827073] | 40 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Within 3 hours from time of culture acquisition, the samples will be vortexed for 30 seconds and 100µl aliquots will be plated onto 5% sheep blood and chocolate agar plates. These plates will be incubated with 5% carbon dioxide at 35˚ C for 72 hours. After 72 hours all plates will be read for colony count and identification of all isolates will be performed using routine microbiological methods. The natural log of bacterial bacterial colony count will be used for the outcome measure. (NCT00827073)
Timeframe: (1) Pre-antibiotics swab, and (2) Post-study medication (pre surgery)
| Intervention | Ln(bacterial colony count) (Mean) |
|---|---|
| Tetracaine 0.5% Drop | -0.14 |
| Lidocaine 2% Jelly | -0.52 |
(NCT00827073)
Timeframe: (1) Pre-antibiotics swab and (2) Post-study medication (pre surgery)
| Intervention | bacterial spceies (Mean) | |
|---|---|---|
| pre number of bacterial spices | post surgery number of bacterial speices | |
| Lidocaine 2% Jelly | 1 | 1 |
| Tetracaine 0.5% Drop | 1 | 1 |
2 trials available for gatifloxacin and Complication, Postoperative
| Article | Year |
|---|---|
Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Double-Blind Method | 2013 |
The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Epithelium, | 2005 |
16 other studies available for gatifloxacin and Complication, Postoperative
| Article | Year |
|---|---|
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprof | 2008 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract E | 2008 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye In | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye In | 2009 |
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Evaluati | 2009 |
Culture-positive endophthalmitis after implantation of intraocular Collamer lens.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; | 2009 |
Gatifloxacin as a possible cause of serious postoperative hypoglycemia.
Topics: Anti-Infective Agents; Blood Glucose; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary | 2005 |
Hyperglycemia and gatifloxacin: a case report and summary of current literature.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Blood Glucose; Coronary Artery Bypass; Fluoroquino | 2005 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Com | 2006 |
Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone.
Topics: Adult; Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Clarithromycin; Corneal Stroma; Debrid | 2006 |
Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
Topics: Ambulatory Surgical Procedures; Anti-Bacterial Agents; Aza Compounds; Drug Costs; Eye Infections, Ba | 2006 |
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds | 2006 |
Effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Anti-Bacterial Agents; Aza Compounds; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolon | 2006 |
Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacter | 2007 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulce | 2008 |
Endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infecti | 2008 |